The present invention relates to the field of myocardial injury. More specifically, the present invention provides methods and compositions useful in the diagnosis, prognosis and/or assessment of myocardial injury. In a specific embodiment, a method comprises the steps of (a) diagnosing a subject as having myocardial injury based on the statistically significant over expression of one or more markers described herein compared to a baseline value, wherein the markers are measured in a biological sample obtained from the subject; and (b) treating the subject with one or more of an anti-thrombolysis agent, coronary bypass surgery or angioplasty.

A method for diagnosis of IgA nephropathy is provided using a combination of alpha-1B-glycoprotein (A1BG) or a truncated fragment thereof having a molecular weight of 13-60 kDa, orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from a subject.

In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa antagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.

The present invention pertains to an in vitro method for detecting intestinal barrier failure in animals, the method comprising the following steps: a) collecting intestinal sample material of an individual animal or of an animal population; and b) determining the amount of at least one protein marker contained in said sample material; wherein the at least one protein marker comprises or consists of ovotransferrin or a functional fragment thereof, and wherein an increased amount of said at least one protein marker contained in said sample versus a reference sample indicates intestinal barrier failure.

The present invention pertains to an in vitro method for detecting intestinal barrier failure in an avian population, the method comprising the following steps: a) collecting a pooled fecal sample deriving from an avian population and b) determining the amount of at least one protein marker contained in said sample; wherein the at least one protein marker comprises or consists of an acute phase protein or a functional fragment thereof, and wherein an increased amount of said at least one protein marker contained in said sample versus a reference sample indicates intestinal barrier failure.

In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb antagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.

The present invention relates to a method for predicting a response to a treatment of an eye disease on the basis of proteome changes. The invention also relates to a kit for use the method.

The present invention provides a method, wherein the method classifies a subject as suffering from dry eye, the method consisting of: a. obtaining demographic data, consisting of the age and gender of the subject; b. obtaining a tear sample from the patient, and determining the level of human serum albumin; c. from the determined level of human serum albumin, assigning a score for the determined amount of human serum albumin; and d. from the assigned score, calculating a cutoff probability score, according to the following equation:

[00001]$\frac{\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}{1+\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}$

wherein the subject has dry eye, if the calculated cutoff probability score is from 50% to 60%.

The present invention provides a method, wherein the method classifies a subject as suffering from dry eye, the method consisting of: a. obtaining demographic data, consisting of the age and gender of the subject; b. obtaining a tear sample from the patient, and determining the level of human serum albumin; c. from the determined level of human serum albumin, assigning a score for the determined amount of human serum albumin; and d. from the assigned score, calculating a cutoff probability score, according to the following equation: wherein the subject has dry eye, if the calculated cutoff probability score is from 50% to 60%. $\frac{\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}{1+\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}$

The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample with a lateral flow device which uses lectin conjugates, anti-antigen conjugates, an immobilized serum line, and an immobilized anti-antigen line.